ImmunityBio Board Changes and Filings
Ticker: IBRX · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Dec 15, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $50,000, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, filing, officer-compensation
Related Tickers: IBRX
TL;DR
ImmunityBio board shakeup: Soon-Shiong out, Adkerson in. Financials filed.
AI Summary
ImmunityBio, Inc. announced on December 10, 2025, a change in its board of directors, with the resignation of Dr. Patrick Soon-Shiong and the appointment of Dr. Richard Adkerson as a new Class III director. The company also disclosed compensatory arrangements for its officers and filed financial statements and exhibits.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while the filing of financial statements provides updates on the company's financial health.
Risk Assessment
Risk Level: medium — Board changes and routine filings can introduce uncertainty or provide new insights into company performance.
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- Dr. Patrick Soon-Shiong (person) — Resigning Director
- Dr. Richard Adkerson (person) — Appointed Director
- December 10, 2025 (date) — Date of earliest event reported
FAQ
Who has resigned from ImmunityBio's board of directors?
Dr. Patrick Soon-Shiong has resigned from the board of directors of ImmunityBio, Inc.
Who has been appointed as a new director to ImmunityBio's board?
Dr. Richard Adkerson has been appointed as a new Class III director.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 10, 2025.
What other items are included in this 8-K filing besides director changes?
This 8-K filing also includes information on compensatory arrangements of certain officers and financial statements and exhibits.
What is the state of incorporation for ImmunityBio, Inc.?
ImmunityBio, Inc. is incorporated in Delaware.
Filing Stats: 1,026 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-12-15 16:25:53
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Select
- $50,000 — director receives cash compensation of $50,000 annually for service as a Board member.
- $300,000 — Company having a Black-Scholes value of $300,000, as computed in accordance with Financi
Filing Documents
- ibrx-20251210.htm (8-K) — 32KB
- 0001326110-25-000146.txt ( ) — 147KB
- ibrx-20251210.xsd (EX-101.SCH) — 2KB
- ibrx-20251210_lab.xml (EX-101.LAB) — 21KB
- ibrx-20251210_pre.xml (EX-101.PRE) — 12KB
- ibrx-20251210_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description of Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: December 15, 2025 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer